The Cellular Products Laboratory (CPL) is dedicated to generation and preparation of quality products for tumor vaccines and for cellular and gene therapy of cancer. This laboratory has assumed an increasingly important role in supporting the conduct of novel immunotherapy clinical trials and gene therapy clinical trials at the UPCI. It performs 3,464 procedures annually and these vary in complexity from large-scale cell production to smaller cultures for research and development purposes. The main users are members of the Biological Therapeutics Program and the Head and Neck Cancer Program. In FY 2002, the CPL services were utilized to support 14 clinical or research protocols. Its responsibilities include cell culture of hematopoietic or non-hematopoietic cells, vaccine preparation, genetic modification of human cells, tissue procurement, processing and distribution for clinical trials, sterility and safety evaluation of each product prior to its administration to patients, and development of new products and procedures for use in future clinical protocols. The CPL pilots preparation of new cellular products, and assists in preparation of INDs. Once IRB and FDA approvals are obtained, the CPL produces and delivers to the bedside therapeutic-grade cells. Recently, generation of dendritic cell (DC)-based vaccines and research associated with therapeutic DC generation have been the major effort, representing nearly 80% of CPL activities. The CPL is operated according to FDA criteria for good manufacturing practice (GMP). The CPL has established a fee-for-service price schedule. The Laboratory has established an excellent record of accomplishments and its unique expertise has enabled rapid translation of novel technologies to clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA047904-17
Application #
6989560
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-09-22
Project End
2009-07-31
Budget Start
2004-09-22
Budget End
2005-07-31
Support Year
17
Fiscal Year
2004
Total Cost
$126,654
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Rogers, Meredith C; Lamens, Kristina D; Shafagati, Nazly et al. (2018) CD4+ Regulatory T Cells Exert Differential Functions during Early and Late Stages of the Immune Response to Respiratory Viruses. J Immunol 201:1253-1266
Chen, Ruochan; Zhu, Shan; Fan, Xue-Gong et al. (2018) High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology 67:1823-1841
Zahorchak, Alan F; Macedo, Camila; Hamm, David E et al. (2018) High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation. Cell Immunol 323:9-18
Singh, Krishna B; Ji, Xinhua; Singh, Shivendra V (2018) Therapeutic Potential of Leelamine, a Novel Inhibitor of Androgen Receptor and Castration-Resistant Prostate Cancer. Mol Cancer Ther 17:2079-2090
Butterfield, Lisa H (2018) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol 52:12-15
Jing, Y; Nguyen, M M; Wang, D et al. (2018) DHX15 promotes prostate cancer progression by stimulating Siah2-mediated ubiquitination of androgen receptor. Oncogene 37:638-650
Krishnamurthy, Anuradha; Dasari, Arvind; Noonan, Anne M et al. (2018) Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res 78:5398-5407
Santos, Patricia M; Butterfield, Lisa H (2018) Next Steps for Immune Checkpoints in Hepatocellular Carcinoma. Gastroenterology 155:1684-1686
Gao, Ying; Tan, Jun; Jin, Jingyi et al. (2018) SIRT6 facilitates directional telomere movement upon oxidative damage. Sci Rep 8:5407
Lontos, Konstantinos; Tsagianni, Anastasia; Yuan, Jian-Min et al. (2018) Location matters in early stage nodal diffuse large B-cell lymphoma. Leuk Lymphoma :1-4

Showing the most recent 10 out of 1187 publications